
Amgen will be 'sensitive to the concerns of payers around cost,' company says

Contract development and manufacturing organizations (CDMOs) want to be more reliable business partners to pharma

More volumes of more valuable products drive growth

Survey shows that most digital channels are still experiments with little oversight or follow-through


With competing products and pricing pressure, the rare disease market is starting to resemble the conventional drug market

Annual survey ranks Good Neighbor Pharmacy as No. 1

The pharma industry needs to go farther in adapting to new marketplace realities


New interfaces and real-time analytics

A 'rebirth' is in the works

Competition continues with Epocrates for market share of doctors' viewership

A nice problem to have; ZS Associates looks at the implications in myeloma

Marken adds real-time wireless tracking; World Courier opens a testing lab in Germany

Megatrends for healthcare supply-chain management

50% expansion adds to facility's pharma capacity; emphasis on cold chain services

District court ruling in favor of Amarin Pharma could radically reshape off-label communications

Thousands of poorly regulated websites are targeted

Logistics company targets courier services as a potential 'service economy' business

DEA basically tells GAO to buzz off

Partners with natural-products chain, Pharmaca, for specialty pharmaceutical access

Amgen, Sanofi-Aventis and Regeneron Pharma win key approvals in the US and EU

Former PhRMA exec will lead GPhA's push for biosimilar approvals

PhRMA rapidly responds: 'a chilling signal to the marketplace that risk-taking will no longer be rewarded'

First new-product release since the IMS Health-Cegedim Relationship Management acquisition

Recent purchase of an MTM company adds to offerings for independent pharmacies

Two-part journey brings a package of medicines to an Appalachian free clinic

Company's patient-assistance program becomes a weapon; meanwhile cure rates as high as 98.4% are being claimed

Labor unions want an end to pharma-sponsored CME